Evidence map›Paper›PMID 35117818›Full record

ArticleTranslational cancer research2020

Rapid identification of novel independent serum biomarkers in diffuse large B-cell lymphoma.

Yi-Qun Che, Di Wang, Peng Liu, Yue Zhang, Yang Luo, Hui-Ying Liu, Di Shen, Wei Cui

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yi-Qun Che *Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Di Wang *Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Peng LiuDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yue ZhangDepartment of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Yang LuoDepartment of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Hui-Ying LiuDepartment of Clinical Laboratory, Jinzhou Central Hospital, Jinzhou, China.
Di ShenDepartment of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Wei CuiDepartment of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiffuse large B-cell lymphoma (DLBCL) is a common subtype of non-Hodgkin's lymphoma (NHL). We assessed serum biomarkers to identify patients with DLBCL and healthy controls, as well as prognosis-related paired pre- and post-R-CHOP therapy effect of patients with DLBCL.

methodsSerum samples from 329 DLBCL patients and 100 healthy controls were collected in this study, as well as 72 samples from additional DLBCL patients with paired pre- and post-R-CHOP therapy (n=36). All serum samples were pretreated and detected by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Serum biomarkers were discriminated between DLBCL patients and healthy controls, as well as between DLBCL patients with prognosis-related paired pre- and post-R-CHOP therapy, and identified by Veristrat Identification Platform 1.0, Bioyong Explore 1.0 and mMass software.

resultsTwo peaks, m/z values of 15,140.74 and 15,885.43, were significantly different from all peaks among the DLBCL patients and healthy controls (P<0.001). Patients with DLBCL could be identified with a sensitivity of 85.9% and specificity of 91.8% of 15,140.74, in the same way for the sensitivity of 92.1% and specificity of 84.4% of 15,885.43. The m/z values of 13,895.80 were downregulated after R-CHOP treatment in DLBCL patients who obtained complete remission (CR) (P=0.018).

conclusionsThe potential independent serum biomarkers for diagnosis as well as prognosis of DLBCL could be provided for rapid identification.

Indexed as

biomarkerdiagnosisdiffuse large B-cell lymphoma (DLBCL)Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS)therapy monitoring

Identifiers

PMID35117818
PMCPMC8797442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.